Q-omics provides the consensus-scored RPS20P33 profile across patient tissues and cancer cell-line models. RPS20P33 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPS20P33 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RPS20P33 RNA expression shows 17,578 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, HNSC, and TGCT as cancer lineages where RPS20P33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS20P33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS20P33 survival associations across molecular data types. RPS20P33 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS20P33 RNA expression–survival associations across cancer types. High RPS20P33 expression shows unfavorable associations in MESO, COAD, STAD, ACC, UVM and UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify MESO as the clearest survival context for RPS20P33 RNA expression.
This table summarizes RPS20P33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS20P33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS20P33 shows higher tumor expression in HNSC, BLCA, COAD, LIHC, LUSC and KIRC. The HNSC box plot shows higher RPS20P33 RNA expression in tumor versus normal tissue (log2 FC = +0.686, t-test p < 0.001).
This table shows molecular features associated with RPS20P33 in patient tissues and cancer cell lines. In patient samples, RPS20P33 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
